Digitally Delivered Dietary Treament for Adult Patients With Irritable Bowel Syndrome: A Pilot Study
1 other identifier
interventional
32
1 country
1
Brief Summary
Two carbohydrate reduced diets, the low FODMAP diet (LFD) and low-carbohydrate diet (LCD), have in randomized controlled studies shown efficacy in relieving symptoms in patients with Irritable Bowel Syndrome (IBS), but access to trained dieticians is limited. Digital delivery may offer a convenient, cost-effective and scalable solution. This pilot study aims to evaluate the effectiveness and feasibility of digitally delivered evidence-based dietary treatments in relieving gastrointestinal, psychological and somatic symptoms and improving quality of life in patients with IBS. Adults with IBS will be recruited via social media and clinical referrals and will receive their choice of the two dietary treatments: LFD with traditional IBS dietary advice or LCD. Participants will get access to the digital platform which contains information about the study, IBS pathophysiology, the treatment diet along with recipes and a mobile application for food scanning. Participants will complete digital questionnaires at baseline and week four to evaluate changes in gastrointestinal symptoms (IBS-SSS), somatic and psychological symptoms (PHQ-15, HADS, VSI) and quality of life (IBS-QoL). Feasibility and adherence is assessed with an evaluation questionnaire.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2025
CompletedFirst Submitted
Initial submission to the registry
May 19, 2026
CompletedFirst Posted
Study publicly available on registry
May 26, 2026
CompletedMay 28, 2026
May 1, 2026
11 months
May 19, 2026
May 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients with significant gastrointestinal symtom reduction
A responder to treatment is defined as having a symptom reduction \> 50 measured by IBS-SSS
From baseline vs 4 weeks after starting digital dietary treatment.
Study Arms (1)
Digital delivery of low FODMAP diet or low-carbohydrate diet
OTHERInterventions
a digital platform with information about the study, IBS, the treatment diet along with recipes and a mobile application for food scanning.
Eligibility Criteria
You may qualify if:
- Diagnosed with IBS (Rome IV) by physician
- Age 18-64
- Ability to read and understand Swedish
- Signed informed consent
You may not qualify if:
- Received dietary treatmen for IBS previously
- Manifestations of other conditions that may explain gastrointestinal symptoms
- Manifestation of other serious medical conditions
- Patients with ongoing eating disorders
- Pregnant/lactating women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sahlgrenska University Hospitallead
- Funding: Kostfondencollaborator
Study Sites (1)
Dept of Internal Medicine, Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
May 19, 2026
First Posted
May 26, 2026
Study Start
May 2, 2024
Primary Completion
April 1, 2025
Study Completion
April 1, 2025
Last Updated
May 28, 2026
Record last verified: 2026-05